TUBB1

Tubulin beta-1 chain · Q9H4B7 · TUBB1 on Sugi Atlas →

148,640 patent compounds predicted against TUBB1, 90,565 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Curacin A Curacin A (SCHEMBL61304) 1.00 20/20
Combretastatin A4 Combretastatin A4 (SCHEMBL18945) 1.00 17/20
Combretastatin A4 Combretastatin A4 (SCHEMBL18946) 1.00 17/20
Fosbretabulin Fosbretabulin (SCHEMBL66079) 0.61 14/20
Vindesine Vindesine (SCHEMBL4420) 0.85 13/20
Vindesine Vindesine (SCHEMBL4421) 0.85 13/20
SCHEMBL68067 SCHEMBL68067 0.62 13/20
Vindesine Vindesine (SCHEMBL4285) 0.85 12/20
Combretastatin Combretastatin (SCHEMBL19955) 1.00 10/20
Combretastatin Combretastatin (SCHEMBL19956) 1.00 10/20
SCHEMBL54200 SCHEMBL54200 0.61 10/20
Thiocolchicine Thiocolchicine (SCHEMBL43160) 1.00 9/20
Thiocolchicine Thiocolchicine (SCHEMBL43161) 1.00 9/20
Centaureidin Centaureidin (SCHEMBL9953) 1.00 8/20
Isovanillin Isovanillin (SCHEMBL70256) 0.61 8/20
SCHEMBL70595 SCHEMBL70595 0.47 8/20
Vinorelbine Vinorelbine (SCHEMBL4765) 1.00 7/20
Colchicine Colchicine (SCHEMBL8469) 1.00 7/20
Levofloxacin Anhydrous Levofloxacin Anhydrous (SCHEMBL15397) 0.98 7/20
Ofloxacin Ofloxacin (SCHEMBL24373) 0.98 7/20

Clinical trials — most relevant to TUBB1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Comparative and Efficacy Study of ACTHar Gel Alone or in Combination With Tacrolimus in Fibrillary Glomerulopathy PHASE4WITHDRAWN
Comparative Analysis of the Efficacies in Neoadjuvant Chemotherapy of Breast Cancer PHASE3COMPLETED
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer PHASE3COMPLETED
Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer PHASE3SUSPENDED
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU) PHASE2/PHASE3ACTIVE_NOT_RECRUITING
The ECLA PHRI COLCOVID Trial. Effects of Colchicine on Moderate/High-risk Hospitalized COVID-19 Patients. PHASE3COMPLETED
Vit D and Peripheral Neuropathy in Taxane Naive Patients PHASE2UNKNOWN
A Multicenter Study of NAP (AL-108) in Schizophrenia PHASE2COMPLETED
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer PHASE2COMPLETED
First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients PHASE2ACTIVE_NOT_RECRUITING
Biologic Correlative Taxotere/AC PHASE2COMPLETED
SB-715992 in Treating Patients With Locally Advanced, Recurrent, or Metastatic Liver Cancer PHASE2COMPLETED
Neoadjuvant Paclitaxel Plus Epirubicin Versus Vinorelbine Plus Epirubicin in Breast Cancer With TEKT4 Variations PHASE2COMPLETED
Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer PHASE2UNKNOWN
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer PHASE1/PHASE2NOT_YET_RECRUITING
Therapy With Docetaxel and ZD1839 for Patients Who Have Advanced Breast Cancer PHASE2COMPLETED
Study of ABT-751 in Patients With Refractory Hematologic Malignancies PHASE1COMPLETED
Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer PHASE1COMPLETED
Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel PHASE1COMPLETED
SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes PHASE1COMPLETED
Exploratory Evaluation of [11C]MPC6827 EARLY_PHASE1COMPLETED
Diagnostic of Chemotherapy Induced Neuropathy in Children nanCOMPLETED
Effect of Low Dose of Colchicine on Platelet Reactivity nanCOMPLETED
Generating Intervals of Reference FFor Early Life Brain Biomarkers. nanRECRUITING
CRF vs WCRF or PRF-DRG in CLBP of FJ Origin and RFA Failure of MBDR: Central Sensitization and Aberrant Nerve Sprouting nanUNKNOWN
Biomarkers in the Diagnosis and Prognosis of NAFLD nanRECRUITING
Correlation Between Autophagy-related Proteins and Inflammatory Markers in Hemodialysis Patients nanCOMPLETED
The Relation of Microtubule-Associated Protein 2 and Cell Migration nanUNKNOWN
Evaluation of a Novel PET Radioligand to Image OGA nanCOMPLETED
Importance of the Microtubule Cytoskeleton in Oocyte Competence nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a TUBB1 binder may also engage these)

ProteinNameSimilarity
Q40106 1.000 Q40106 →
Q6VAF4 1.000 Q6VAF4 →
Q9ZPN9 1.000 Q9ZPN9 →
Q43697 1.000 Q43697 →
Q41785 1.000 Q41785 →
P29515 1.000 P29515 →
Q41782 1.000 Q41782 →
Q8H7U1 1.000 Q8H7U1 →
P12411 1.000 P12411 →
P18025 1.000 P18025 →
Q76FS3 1.000 Q76FS3 →
P05304 1.000 P05304 →
Q6VAF7 1.000 Q6VAF7 →
Q39697 1.000 Q39697 →
Q9ZRB0 1.000 Q9ZRB0 →
P09652 1.000 P09652 →
Q9ZPP0 1.000 Q9ZPP0 →
P93176 1.000 P93176 →
Q76FS2 1.000 Q76FS2 →
Q24560 1.000 Q24560 →
Q4P235 1.000 Q4P235 →
Q92268 1.000 Q92268 →
Q9ERD7 1.000 Q9ERD7 →
Q4QRB4 1.000 Q4QRB4 →
P10878 1.000 P10878 →
Q9NFZ5 1.000 Q9NFZ5 →
P16040 1.000 P16040 →
P08562 1.000 P08562 →
Q3ZBU7 1.000 Q3ZBU7 →
Q52NY7 1.000 Q52NY7 →